These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8279773)

  • 1. The EBCTCG overview of adjuvant therapy of breast cancer. What are the implications for future studies? Early Breast Cancer Trialists' Collaborative Group.
    Gray R; Clarke M; Collins R; Peto R
    Ann N Y Acad Sci; 1993 Nov; 698():339-48. PubMed ID: 8279773
    [No Abstract]   [Full Text] [Related]  

  • 2. Endocrine factors in the outcome of systemic adjuvant therapy of early breast cancer.
    Bianco AR; De Placido S; Perrone F; Carlomagno C; De Laurentiis M; Del Mastro L; Lauria R; Marinelli A; Gallo C
    Ann N Y Acad Sci; 1993 Nov; 698():330-8. PubMed ID: 8279772
    [No Abstract]   [Full Text] [Related]  

  • 3. The place of chemotherapy in the treatment of early breast cancer.
    Buzdar A
    Br J Cancer; 1998 Sep; 78 Suppl 4(Suppl 4):16-20. PubMed ID: 9741784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scottish adjuvant breast cancer trials: results in pre-menopausal patients.
    Stewart HJ
    Recent Results Cancer Res; 1989; 115():126-31. PubMed ID: 2696025
    [No Abstract]   [Full Text] [Related]  

  • 5. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. boccardo@hp380.ist.unige.it.
    Boccardo F; Rubagotti A; Amoroso D; Mesiti M; Romeo D; Sismondi P; Giai M; Genta F; Pacini P; Distante V; Bolognesi A; Aldrighetti D; Farris A
    J Clin Oncol; 2000 Jul; 18(14):2718-27. PubMed ID: 10894871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
    International Breast Cancer Study Group (IBCSG)
    J Natl Cancer Inst; 2002 Jul; 94(14):1054-65. PubMed ID: 12122096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.
    Lancet; 1992 Jan; 339(8785):71-85. PubMed ID: 1345869
    [No Abstract]   [Full Text] [Related]  

  • 8. Ovarian suppression/ablation in premenopausal ER-positive breast cancer patients. Issues and recommendations.
    Pritchard KI
    Oncology (Williston Park); 2009 Jan; 23(1):27-33. PubMed ID: 19283918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5.
    Jakesz R; Hausmaninger H; Kubista E; Gnant M; Menzel C; Bauernhofer T; Seifert M; Haider K; Mlineritsch B; Steindorfer P; Kwasny W; Fridrik M; Steger G; Wette V; Samonigg H;
    J Clin Oncol; 2002 Dec; 20(24):4621-7. PubMed ID: 12488405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Critical review of adjuvant therapy in premenopausal patients.
    Mouridsen HT
    Recent Results Cancer Res; 1989; 115():132-5. PubMed ID: 2623330
    [No Abstract]   [Full Text] [Related]  

  • 11. Luteinizing hormone-releasing hormone analogues in early breast cancer: updated status of ongoing clinical trials.
    Kaufmann M
    Br J Cancer; 1998 Sep; 78 Suppl 4(Suppl 4):9-11. PubMed ID: 9741782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tamoxifen: a review of pharmacoeconomic and quality-of-life considerations for its use as adjuvant therapy in women with breast cancer.
    Bryson HM; Plosker GL
    Pharmacoeconomics; 1993 Jul; 4(1):40-66. PubMed ID: 10146967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meeting highlights: International consensus panel on the treatment of primary breast cancer.
    Love RR
    J Clin Oncol; 2002 Apr; 20(7):1955-6; author reply 1956-7. PubMed ID: 11919263
    [No Abstract]   [Full Text] [Related]  

  • 14. Endocrine effects of adjuvant chemotherapy in premenopausal women: suggestions for the future.
    Tormey DC
    Recent Results Cancer Res; 1989; 115():106-12. PubMed ID: 2623329
    [No Abstract]   [Full Text] [Related]  

  • 15. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
    Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
    Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer.
    Ejlertsen B; Jensen MB; Elversang J; Rasmussen BB; Andersson M; Andersen J; Nielsen DL; Cold S; Mouridsen HT
    Eur J Cancer; 2013 Sep; 49(14):2986-94. PubMed ID: 23756360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant oophorectomy versus CMF in premenopausal node-positive breast cancer: long-term results of an experience at the Milan Cancer Institute.
    Salvadori B; Celio L; Oriana R; Bajetta E
    Tumori; 2000; 86(3):258-9. PubMed ID: 10939610
    [No Abstract]   [Full Text] [Related]  

  • 18. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
    Misset JL; di Palma M; Delgado M; Plagne R; Chollet P; Fumoleau P; Le Mevel B; Belpomme D; Guerrin J; Fargeot P; Metz R; Ithzaki M; Hill C; Mathé G
    J Clin Oncol; 1996 Apr; 14(4):1136-45. PubMed ID: 8648368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival.
    Gelber RD; Cole BF; Goldhirsch A; Rose C; Fisher B; Osborne CK; Boccardo F; Gray R; Gordon NH; Bengtsson NO; Sevelda P
    Lancet; 1996 Apr; 347(9008):1066-71. PubMed ID: 8602056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of tamoxifen in breast cancer.
    Gau TC
    Postgrad Med; 1985 Jun; 77(8):21-2. PubMed ID: 3839078
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.